[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Inenaga C, Morii K, Tamura T, Tanaka R, Takahashi H: Mesenchymal chondrosarcoma of the sellar region. Acta Neurochir (Wien); 2003 Jul;145(7):593-7; discussion 597
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, no such malignant tumour has been described in the sellar region.
  • Upon initial admission, no endocrinological abnormalities were found, and computed tomography and magnetic resonance imaging revealed a mass with calcification in the sella and right cavernous sinus.
  • INTERVENTION: For this malignant tumour, three surgical resections, two sessions of gamma-knife radiosurgery, one session of fractional irradiation, and one cycle of chemotherapy were performed, resulting in only brief arrest of the tumour growth.
  • Pathologically, the tumour consisted of undifferentiated small cells of high cellularity, and islands of hyaline cartilage.
  • CONCLUSION: Although malignant tumours in the sellar region are rare, they should be considered in the differential diagnosis of various sellar tumours typified by non-functioning pituitary adenoma, and mesenchymal chondrosarcoma is one possible candidate.

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12910404.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


2. Yaman E, Benekli M, Coskun U, Sezer K, Ozturk B, Kaya AO, Yildiz R, Uluoglu O, Buyukberber S: Intrasellar plasmacytoma: an unusual presentation of multiple myeloma. Acta Neurochir (Wien); 2008 Sep;150(9):921-4; discussion 924
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Occasionally, they can be misdiagnosed as a nonfunctioning adenoma because of radiological and clinical similarities.
  • Initial diagnosis of a nonfunctioning pituitary adenoma was later overruled by a repeat biopsy, which showed a plasmacytoma.
  • The tumor stained positively for CD138 and kappa light chain.
  • Further studies confirmed the diagnosis of multiple myeloma.
  • The patient was successfully treated with radiotherapy followed by systemic chemotherapy.
  • Because they have different therapeutic implications, extramedullary plasmacytomas involving pituitary gland should be considered in the differential diagnosis of a nonfunctioning pituitary mass.
  • [MeSH-major] Multiple Myeloma / complications. Multiple Myeloma / diagnosis. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / etiology. Plasmacytoma / diagnosis. Plasmacytoma / etiology
  • [MeSH-minor] Adenoma / diagnosis. Aged. Biopsy. Diagnosis, Differential. Female. Humans. Immunoglobulin kappa-Chains / metabolism. Magnetic Resonance Imaging. Sella Turcica. Syndecan-1 / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726062.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Immunoglobulin kappa-Chains; 0 / Syndecan-1
  • [Number-of-references] 24
  •  go-up   go-down


3. Gur C, Lalazar G, Salmon A, Dubiner V, Gross DJ: Metastatic pancreatic neuroendocrine tumor presenting as a pituitary space occupying lesion: a case report. Pituitary; 2008;11(3):293-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic pancreatic neuroendocrine tumor presenting as a pituitary space occupying lesion: a case report.
  • Neuroendocrine tumor metastases to the pituitary gland are very rare.
  • There are few case reports of carcinoid tumor metastases to the pituitary, but no cases of pancreatic neuroendocrine pituitary metastases have been reported.
  • In this report we present a 55-year-old female with a sellar mass, ophthalmoplegia and headaches initially thought to represent an invasive null cell pituitary adenoma.
  • However a histological (trans-sphenoidal and liver biopsies) and systemic investigation proved it to be a metastasis of an undiagnosed pancreatic neuroendocrine tumor.
  • Our patient was unique in respect to the location of the metastasis and the uncharacteristically high proliferative index of her tumor.
  • She received conventional therapy consisting of Sandostatin, chemotherapy and radiotherapy as well as labeled somatostatin following an avid uptake on octreotide scanning.
  • [MeSH-major] Neuroendocrine Tumors / secondary. Pancreatic Neoplasms / pathology. Pituitary Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Middle Aged. Radiotherapy, Adjuvant. Tomography, Emission-Computed, Single-Photon


Advertisement
4. Zhang W, Murao K, Imachi H, Iwama H, Chen K, Fei Z, Zhang X, Ishida T, Tamiya T: Suppression of prolactin expression by cabergoline requires prolactin regulatory element-binding protein (PREB) in GH3 cells. Horm Metab Res; 2010 Jul;42(8):557-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prolactin regulatory element-binding protein (PREB) is a transcriptional factor that regulates prolactin (PRL) promoter activity in the anterior pituitary.
  • Prolactinomas are the most common pituitary tumors.
  • Administration of cabergoline, a selective dopamine D2-receptor agonist, has become the initial therapy of choice for most patients with prolactinomas.
  • Samples of ten prolactinomas and ten nonfunctioning pituitary adenomas were analyzed by immunohistochemistry to detect the expression of PREB.
  • The effect of cabergoline on PREB expression was assessed by western blotting and real-time polymerase chain reaction (PCR) analysis.
  • Immunohistochemical analysis revealed strong positive PREB expression in the prolactinoma tissue, but extremely weak or undetected expression in the nonfunctioning pituitary tumor tissue.
  • Western blots probed with a PREB-specific antiserum revealed that the relative abundance of the PREB protein in the GH3 cells decreased in a dose-dependent manner in response to cabergoline treatment, as did the relative abundance of PREB mRNA.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Down-Regulation / drug effects. Ergolines / pharmacology. Guanine Nucleotide Exchange Factors / metabolism. Prolactin / genetics. Transcription Factors / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Prolactinoma / metabolism. Prolactinoma / pathology. Promoter Regions, Genetic / genetics. Transcription, Genetic / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20411477.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Ergolines; 0 / Guanine Nucleotide Exchange Factors; 0 / PREB protein, human; 0 / Transcription Factors; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  •  go-up   go-down


5. Svensson J, Finer N, Bouloux P, Bevan J, Jonsson B, Mattsson AF, Lundberg M, Harris PE, Koltowska-Häggström M, Monson JP, KIMS International Board: Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Horm IGF Res; 2007 Feb;17(1):67-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response.
  • OBJECTIVE: This study investigated whether baseline status could predict the responsiveness to one-year growth hormone (GH) replacement therapy in adult GH deficient (GHD) patients.
  • DESIGN: A total of 380 European patients with adult onset GHD due to non-functioning pituitary adenoma that had been enrolled in Pfizer International Metabolic Database (KIMS), and that had completed one year of GH replacement therapy within KIMS, were studied.
  • Quality of life (QoL)-Assessment of GHD in Adults (QoL-AGHDA), waist circumference, waist:hip ratio, and serum lipid pattern improved.
  • Women received a higher dose of GH than men after one year, and demonstrated similar treatment response.
  • In multiple stepwise forward regression analyses, the one-year changes in QoL-AGHDA score, waist:hip ratio, and serum low density lipoprotein-cholesterol (LDL-C) level correlated inversely with the baseline values of the same variable.
  • In addition, the change after one year in QoL-AGHDA score correlated inversely with duration of hypopituitarism and baseline serum high density lipoprotein-cholesterol (HDL-C) level, and the change in waist:hip ratio correlated inversely, although more weakly, with baseline serum HDL-C level and UK citizenship and positively with baseline waist circumference and the initial GH dose.
  • Therefore, when the decision to start GH replacement is undertaken, as many outcome variables as possible should be evaluated in order to adequately evaluate the likelihood of clinical benefit.
  • Finally, women have a similar response to GH replacement as men when individualised GH dosing schedules are employed and should therefore be selected for GH therapy to a similar extent.
  • [MeSH-major] Dwarfism, Pituitary / diagnosis. Dwarfism, Pituitary / drug therapy. Growth Hormone / therapeutic use. Hormone Replacement Therapy
  • [MeSH-minor] Cohort Studies. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Models, Statistical. Prognosis. Quality of Life. Sex Characteristics. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17223598.001).
  • [ISSN] 1096-6374
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


6. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P: Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab; 2001 Jan;86(1):140-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
  • Although both somatostatin receptor subtype 2 (SSTR2) and SSTR5 messenger ribonucleic acid (mRNA) are consistently expressed in GH-secreting adenomas, SSTR2 has been believed to be the key modulator of somatostatin-mediated inhibition of GH release.
  • Recently, however, it was demonstrated that an SSTR5 preferential agonist, BIM-23268, not only suppressed PRL release from prolactinomas and mixed GH-PRL adenomas, but also inhibited GH release in about half of GH adenomas.
  • In addition, the SSTR5-preferring analog showed a slight additive effect when used in combination with SSTR2 preferential drugs at submaximal concentrations in octreotide partially sensitive adenomas.
  • In the present study we quantified SSTR2 and SSTR5 mRNA expression and the GH-suppressive effects of somatostatin-14; octreotide; a SSTR2-preferential compound, BIM-23197; a SSTR5-preferential compound, BIM-23268; and a new SSTR2- and SSTR5-bispecific compound, BIM-23244, in GH-secreting tumors classified as either full responders to octreotide (n = 5) or partially sensitive to octreotide (n = 5).
  • The octreotide-sensitive GH secretory adenomas presented with a high level of both SSTR2 and SSTR5 mRNA expression [222 +/- 61 and 327 +/- 136 pg/pg glyceraldehyde-3-phosphate dehydrogenase (GAPDH), respectively].
  • In these tumors the suppression of GH release was similarly achieved at picomolar ranges by octreotide, BIM-23197, and BIM-23244 (EC(50) = 25 +/- 15, 3 +/- 2, and 3 +/- 3 pmol/L, respectively).
  • The compounds preferential for only SSTR5 were unable to inhibit GH release in such tumors.
  • Among the octreotide partially responsive tumors, SSTR2 mRNA expression was 9-fold lower than in the octreotide-sensitive tumors (25 +/- 12 vs. 222 +/- 61 pg/pg GAPDH; P < 0.015), whereas SSTR5 mRNA expression was approximately 7-fold higher than in the octreotide-sensitive tumors (2271 +/- 1197 pg/pg GAPDH).
  • In these octreotide partially responsive tumors, the SSTR5-preferential compound, BIM-23268, and the SSTR2- and SSTR5-bispecific compound, BIM-23244, were quite effective in suppressing GH secretion (EC(50) = 25 +/- 13 and 50 +/- 31 pmol/L, respectively).
  • Similarly, BIM-23244, was able to suppress by 51 +/- 5% PRL release from five mixed GH- and PRL-secreting adenomas.
  • These data indicate that due to heterogeneous expression of SSTR2 and SSTR5 receptor subtypes, in GH-secreting tumors, a bispecific analog, such as BIM-23244, that can activate both receptors could achieve better control of GH hypersecretion in a larger number of acromegalic patients.
  • [MeSH-major] Adenoma / secretion. Human Growth Hormone / antagonists & inhibitors. Human Growth Hormone / secretion. Octreotide / therapeutic use. Pituitary Neoplasms / secretion. Receptors, Somatostatin / therapeutic use. Somatostatin / analogs & derivatives
  • [MeSH-minor] Acromegaly / drug therapy. Acromegaly / metabolism. Adult. Drug Resistance. Female. Hormones / therapeutic use. Humans. Male. Middle Aged. Prolactin / secretion. RNA, Messenger / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11231991.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIM-23244; 0 / Hormones; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 9002-62-4 / Prolactin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


7. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodoropoulou M: The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res; 2010 Jan 15;70(2):666-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells.
  • Rapamycin and its analogues have significant antiproliferative action against a variety of tumors.
  • Here, we investigated this model using the somatostatin analogue octreotide as a tool to decrease levels of activated Ser(473)-phosphorylated Akt (pAkt-Ser(473)) in pituitary tumor cells that express somatostatin receptors.
  • Octreotide potentiated the antiproliferative effects of rapamycin in immortalized pituitary tumor cells or human nonfunctioning pituitary adenoma cells in primary cell culture, sensitizing tumor cells even to low rapamycin concentrations.
  • Combined treatment of octreotide and rapamycin triggered G(1) cell cycle arrest, decreasing E2F transcriptional activity and cyclin E levels by increasing levels of p27/Kip1.
  • These findings show that adjuvant treatment with a somatostatin analogue can sensitize pituitary tumor cells to the antiproliferative effects of rapamycin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Octreotide / pharmacology. Pituitary Neoplasms / drug therapy. Sirolimus / pharmacology
  • [MeSH-minor] Adenoma / drug therapy. Adenoma / metabolism. Adenoma / pathology. Cell Cycle / drug effects. Cell Growth Processes / drug effects. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis. Drug Synergism. Humans. Insulin Receptor Substrate Proteins / metabolism. Oncogene Protein v-akt / metabolism. Phosphorylation / drug effects. Up-Regulation


8. Lin SH, Hung YH, Lin YF: Severe hyponatremia as the presenting feature of clinically non-functional pituitary adenoma with hypopituitarism. Clin Nephrol; 2002 Jan;57(1):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hyponatremia as the presenting feature of clinically non-functional pituitary adenoma with hypopituitarism.
  • We present two cases in which severe hyponatremia developed with weakness, light-headedness and seizure.
  • Computerized tomography of the brain revealed an adenoma of the pituitary gland.
  • These two cases illustrate that severe hyponatremia may be the presenting feature of clinically non-functional pituitary adenoma with hypopituitarism, which should be kept in mind in the differential diagnosis of hyponatremia mimicking SIADH.
  • [MeSH-major] Adenoma / complications. Hyponatremia / etiology. Pituitary Neoplasms / complications
  • [MeSH-minor] Aged. Anti-Inflammatory Agents / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Thyroid Hormones / therapeutic use. Thyroxine / administration & dosage. Vasopressins / blood. Vasopressins / deficiency

  • Genetic Alliance. consumer health - Hypopituitarism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11837807.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Thyroid Hormones; 11000-17-2 / Vasopressins; 9PHQ9Y1OLM / Prednisolone; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


9. Deniz K, Tanriverdi F, Selçuklu A, Kontaş O, Keleştimur F: Signet ring-like cells in pituitary adenoma. Pathol Res Pract; 2008;204(3):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet ring-like cells in pituitary adenoma.
  • We describe a case of non-functioning pituitary adenoma in a 35-year-old woman with a prior history of fertility problems.
  • Histological examination of the tumor revealed signet ring-like cell areas admixed with minor conventional round-polygonal neoplastic cells.
  • The two populations of tumor cells showed strong immunoreactivity for chromogranin and synaptophysin.
  • [MeSH-major] Adenoma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adult. Chorionic Gonadotropin / therapeutic use. Chromogranins / metabolism. Clomiphene / therapeutic use. Female. Fertility Agents, Female / therapeutic use. Headache / etiology. Humans. Immunohistochemistry. Infertility, Female / drug therapy. Magnetic Resonance Imaging. Synaptophysin / metabolism. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. CLOMIPHENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207654.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Chromogranins; 0 / Fertility Agents, Female; 0 / Synaptophysin; 1HRS458QU2 / Clomiphene
  •  go-up   go-down


10. Trimarchi CP, Russo P: Cyclic estrogen-progestin hormone therapy as a new therapeutic approach in the treatment of functional alterations of the hypothalamus-pituitary-ovary axis: case reports. Endocr Res; 2002 Aug;28(3):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclic estrogen-progestin hormone therapy as a new therapeutic approach in the treatment of functional alterations of the hypothalamus-pituitary-ovary axis: case reports.
  • We report a first case of a 30 year-old woman affected by polycystic ovarian disease (PCOD) whose amenorrhea ceased after a 6-month combination treatment with cyclic estradiol-norethisterone acetate.
  • After the withdrawal of the hormone therapy, a stable recovery of periodic menses was observed.
  • We describe a second case of a 23 year-old woman whose amenorrhea was caused by a hypogonadotropic hypogonadism due to a non-functioning pituitary adenoma.
  • After the administration of the previously described therapy both a disappearance of the adenoma and a recover of periodic menses were observed.
  • The exogenous hormones may have reset the feedback between the hypothalamus and pituitary gland through mimicking the physiological hormones pattern of the 28-day cycle.
  • [MeSH-major] Adenoma / complications. Amenorrhea / drug therapy. Estradiol / administration & dosage. Norethindrone / administration & dosage. Norethindrone / analogs & derivatives. Pituitary Neoplasms / complications. Polycystic Ovary Syndrome / complications
  • [MeSH-minor] Adult. Drug Administration Schedule. Drug Therapy, Combination. Feedback. Female. Humans. Hypogonadism / complications. Hypothalamus / drug effects. Hypothalamus / physiopathology. Ovary / physiopathology. Pituitary Gland / drug effects. Pituitary Gland / physiopathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. NORETHINDRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12489565.001).
  • [ISSN] 0743-5800
  • [Journal-full-title] Endocrine research
  • [ISO-abbreviation] Endocr. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9S44LIC7OJ / norethindrone acetate; T18F433X4S / Norethindrone
  •  go-up   go-down


11. Losa M, Mortini P, Giovanelli M: [The role of somatostatin analogues in the treatment of hypophyseal adenomas]. Minerva Endocrinol; 2003 Mar;28(1):39-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
  • Somatostatin analogues are widely employed in the treatment of hypophyseal adenomas.
  • The most widely used analogues at the present time are octreotide and lanreotide.
  • Both octreotide and lanreotide have proved their effectiveness in the treatment of GH- and TSH-secretory hypophyseal adenomas.
  • In those patients who respond to pharmacological treatment we often achieve not only the control of hormonal hypersecretion, but also a reduction in the volume of hypophyseal neoplasia.
  • In the other types of hypophyseal adenoma, on the other hand, somatostatin analogues have proved to have little effect: apart from isolated cases of effectiveness in non-functioning adenomas, the administration both of octreotide and lanreotide to patients with Cushing's disease or prolactinoma did not significantly modify the hormonal hypersecretion or tumoural volume.
  • The side-effects of somatostatin analogues are comparatively rare and of moderate entity: only a small percentage of patients requires the treatment to be suspended owing to the occurrence of side-effects.
  • Octreotide, bound to radioactive substances or to toxins, has also been utilised for the selective destruction of neoplastic tissues expressing the sst(2) receptor of somatostatin.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / analogs & derivatives
  • [MeSH-minor] Acromegaly / drug therapy. Acromegaly / etiology. Adrenocorticotropic Hormone / secretion. Combined Modality Therapy. Cushing Syndrome / drug therapy. Cushing Syndrome / etiology. Forecasting. Human Growth Hormone / secretion. Humans. Insulin-Like Growth Factor I / secretion. Octreotide / adverse effects. Octreotide / pharmacology. Octreotide / therapeutic use. Peptides, Cyclic / adverse effects. Peptides, Cyclic / pharmacology. Peptides, Cyclic / therapeutic use. Prolactinoma / drug therapy. Radiopharmaceuticals / therapeutic use. Receptors, Somatostatin / drug effects. Receptors, Somatostatin / physiology. Thyrotropin / secretion. Treatment Outcome. Yttrium Radioisotopes / therapeutic use

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621362.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Peptides, Cyclic; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 0 / Yttrium Radioisotopes; 118992-92-0 / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; 9002-60-2 / Adrenocorticotropic Hormone; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 79
  •  go-up   go-down


12. Guerra Y, Lacuesta E, Marquez F, Raksin PB, Utset M, Fogelfeld L: Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Pituitary; 2010;13(1):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.
  • We report the case of a 60 year old male who complained of headache and blurry vision--that progressed to left ophthalmoplegia and ptosis--after receiving a dose of leuprolide for Prostate cancer therapy.
  • The patient underwent transsphenoidal debulking, and the tissue obtained demonstrated immunohistochemical staining for LH.
  • A literature review revealed nine previously reported cases of pituitary apoplexy after GnRH agonist therapy for prostate cancer.
  • In most cases, the sellar tissues stained for LH, consistent with a gonadotropinoma.
  • Particular attention to clinical findings suggestive of a non functioning pituitary tumor in patients receiving GnRH agonist therapy is critical as routine screening with MRI is not practical.
  • [MeSH-major] Adenoma / complications. Leuprolide / adverse effects. Pituitary Neoplasms / complications. Stroke / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Humans. Male. Middle Aged. Prostatic Neoplasms / complications. Prostatic Neoplasms / drug therapy. Sella Turcica


13. Colao A, Dorato M, Pulcrano M, Rossi FW, Auriemma RS, Lombardi G, Lastoria S: [Somatostatin analogs in the clinical management of pituitary neoplasms]. Minerva Endocrinol; 2001 Sep;26(3):181-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Somatostatin analogs in the clinical management of pituitary neoplasms].
  • The medical approach to patients with secreting or clinically non-functioning pituitary adenoma as made considerable progress thanks to the use of new somatostatin analogs.
  • Good results were obtained using slow-release analog treatment also in TSH-secreting adenomas, whereas the therapeutic efficacy of these peptides in clinically non-functioning adenomas is still controversial.
  • Treatment with somatostatin analogs improves symptoms, normalises hormone secretion and in some cases may induce a reduction in the volume of pituitary adenomas.
  • Scintigraphy with octreotide may help to select patients who respond to this form of treatment.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / analogs & derivatives. Octreotide / therapeutic use. Pentetic Acid / analogs & derivatives. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / therapeutic use
  • [MeSH-minor] Acromegaly / drug therapy. Adolescent. Adrenal Gland Neoplasms / radionuclide imaging. Adult. Aged. Carcinoma / radionuclide imaging. Humans. Indium Radioisotopes / therapeutic use. Insulin-Like Growth Factor I / secretion. Kidney Neoplasms / radionuclide imaging. Melanoma / radionuclide imaging. Middle Aged. Pheochromocytoma / radionuclide imaging. Predictive Value of Tests. Prolactinoma / drug therapy. Radiopharmaceuticals / therapeutic use. Sensitivity and Specificity. Thymoma / radionuclide imaging. Thymus Neoplasms / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging. Thyrotropin / secretion. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11753242.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Indium Radioisotopes; 0 / Peptides, Cyclic; 0 / Radiopharmaceuticals; 118992-92-0 / lanreotide; 142694-57-3 / SDZ 215-811; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; 7A314HQM0I / Pentetic Acid; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 95
  •  go-up   go-down


14. Kreitschmann-Andermahr I, Poll EM, Reineke A, Gilsbach JM, Brabant G, Buchfelder M, Fassbender W, Faust M, Kann PH, Wallaschofski H: Growth hormone deficient patients after traumatic brain injury--baseline characteristics and benefits after growth hormone replacement--an analysis of the German KIMS database. Growth Horm IGF Res; 2008 Dec;18(6):472-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All 84 TBI patients were matched with 84 patients with GHD due to non-functioning pituitary adenoma (NFPA) also included in this database.
  • Analysis of clinical and outcome variables was performed, with comparisons of childhood vs. adult TBI, and TBI vs. NFPA patients, at baseline and one-year follow-up.
  • RESULTS: TBI patients with GHD were significantly younger at the onset of pituitary disease and exhibited a significantly longer time span between GHD diagnosis and KIMS entry than NFPA patients.
  • At 1-year follow-up, insulin-like growth factor I (IGF-I) standard deviation score levels had returned to the normal range and quality of life (QoL), as measured by QoL- Assessment of Growth Hormone Deficiency in Adults (AGHDA) questionnaire, improved significantly in TBI as in NFPA patients.
  • CONCLUSION: This analysis provides preliminary data that TBI patients with GHD benefit from hGH replacement in terms of improved QoL in a similar fashion as do NFPA patients.
  • Moreover, it suggests that belated diagnosis and treatment in childhood-onset GHD due to TBI might be related to a shorter final height in these children.
  • [MeSH-major] Brain Injuries / physiopathology. Databases, Factual. Human Growth Hormone / therapeutic use
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Germany. Hormone Replacement Therapy. Humans. Hypopituitarism / complications. Hypopituitarism / drug therapy. Hypopituitarism / physiopathology. Male. Middle Aged. Pituitary Neoplasms / complications. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829359.001).
  • [ISSN] 1532-2238
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


15. Andersen M, Bjerre P, Schrøder HD, Edal A, Høilund-Carlsen PF, Pedersen PH, Hagen C: In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf); 2001 Jan;54(1):23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
  • The secretory capacity, in vivo, of clinically non-functioning pituitary adenomas may possibly predict tumour volume reduction during intensive medical therapy.
  • Ten patients (mean (range) 53 years (26-73)) with clinically non-functioning macroadenomas, > or = 10 mm were studied.
  • The secretory capacity of the adenomas was examined using basal, NaCl and TRH-stimulated LH, FSH and alpha-subunit levels.
  • The effect on tumour volume of 6 months' therapy with the combination of a somatostatin analogue, octreotide 200 microg x 3/day and a dopamine-D2-agonist, cabergoline 0.5 mg x 1/day was studied.
  • The basal LH, FSH and alpha-subunit levels were determined before and during 6 months' therapy with octreotide and cabergoline, and MR scans were used to evaluate tumour volume before and during this period of therapy.
  • A reduction in tumour volume (mean +/- SEM (range); 30% +/- 4% (18-46%)) during 6 months of combination therapy with octreotide and cabergoline was recorded only in patients with in vivo secretory potential.
  • Tumour volume was not reduced in four patients: in three of these patients it remained unchanged while in one patient it was observed to have increased (by 14%).
  • Of the six patients with pretherapy secretory capacity, one displayed a very high basal level of alpha-subunit (74 microg/l) despite unmeasurable levels of LH and TSH, and an FSH-level of 1 IU/l.
  • During six months of therapy with octreotide and cabergoline, the basal levels of LH, FSH and alpha-subunit were reduced by > or = 50% in seven patients - including the six patients with in vivo secretion prior to therapy.
  • No new visual field defects were detected during therapy and no deterioration of existing visual field defects was recorded.
  • The medical therapy was well tolerated.
  • The in vivo basal and TRH-stimulated secretory capacity of LH, FSH and alpha-subunit predicted tumour reduction following intensive medical therapy in all of our patients with non-functioning pituitary adenomas.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / secretion. Antineoplastic Agents, Hormonal / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / secretion
  • [MeSH-minor] Adult. Aged. Dopamine Agonists / therapeutic use. Drug Therapy, Combination. Ergolines / therapeutic use. Female. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Male. Middle Aged. Octreotide / therapeutic use. Prognosis. Thyrotropin / blood

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11167922.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Dopamine Agonists; 0 / Ergolines; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide
  •  go-up   go-down






Advertisement